SCHEMBL189282

SCHEMBL189282

OCCCOc1ccc(-c2cc(CO)on2)cc1

nearest known ligand 0.59

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 2/20 0.59
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
L3MBTL1 Q9Y468 4/20 0.49
NPC1 O15118 3/20 0.49
TDP1 Q9NUW8 3/20 0.49
MAPT P10636 3/20 0.49
XDH P47989 2/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
CXCR1 P25024 2/20 0.45
CYP1A2 P05177 2/20 0.44
SMPD1 P17405 1/20 0.43
CYP2D6 P10635 1/20 0.42
CYP19A1 P11511 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189961 0.87 NOTUM (0.61) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL1566577 0.80 SMN1; SMN2 (0.64) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL189559 0.79 NOTUM (0.66) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL189986 0.79 XDH (0.49) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL189713 0.78 MAPK1 (0.56) MEN1KMT2A
SCHEMBL189217 0.77 NOTUM (0.52) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL15104544 0.77 NOTUM (0.59) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL27331707 0.76 NOTUM (0.58) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL190253 0.76 SMN1; SMN2 (0.49) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1
SCHEMBL3233333 0.76 NOTUM (0.72) NOTUMRAB9ASMN1; SMN2L3MBTL1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 NOTUM 1260/4885RAB9A 1245/4885SMN1; SMN2 268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.